CClinicalTrials.gg
CompletedNCT01331564eMOMSUpdated Dec 2, 2015

eMOMS of Rochester

A Phase 3 interventional study of electronic intervention during pregnancy and postpartum and electronic intervention during pregnancy in Gestational Weight Gain and Postpartum Weight Retention, sponsored by University of Rochester. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-02.

Sponsored by University of Rochester · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
1,641
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The project aims to develop, implement and evaluate electronically-mediated behavioral intervention programs for pregnant and postpartum women in order to prevent excessive weight gain during pregnancy and postpartum weight retention.

Read the detailed description

This study seeks to expand the understanding of how to slow the accumulation of weight in childbearing women. The intervention goals are to decrease the prevalence of excessive pregnancy weight gain and mean weight retention in the first 18 months postpartum in socio-economically and racially/ethnically diverse sample of 1,641 pregnant women. Women will be randomly assigned to one of three groups: Intervention Group 1 will receive the intervention program only during pregnancy (e-intervention 1). Intervention Group 2 will receive e-intervention 1 plus intervention for 18 months postpartum (e-intervention 2). Control women will receive non-weight related content during both time periods at the project website. The primary hypotheses for the randomized controlled trial are: H1: The proportion of women in Intervention Groups 1 and 2 who gain more weight in pregnancy than is recommended by the IOM will be 33% less than the proportion of the women in the Control Group who gain excessively and H2: The Control Group will have a higher mean weight retention at 12 months postpartum than Intervention Groups 1 and 2.

02

Conditions studied

  • Gestational Weight Gain
  • Postpartum Weight Retention

Keywords

  • Pregnancy
  • Postpartum
  • Weight gain
  • Weight retention
  • Behavior
  • Electronic Media
  • Randomized Clinical Trial
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's enrollment of 1,641 is above the median of 64 across 947 interventional studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18 - 35 at the time of delivery
  • Consented at or before 20 weeks gestation
  • Intending to be available for a 24 months intervention
  • Plan to deliver in one of the 4 hospitals in Rochester, NY (the study area)
  • Plan to carry the pregnancy to term
  • Plan to keep the baby
  • Read and understand English

Exclusion criteria

Exclusion Criteria:

  • BMI \< 18.5 kg/m2 and > 35.0 kg/m2.
  • Multiple gestation. If multiple gestation is diagnosed after enrollment participant will be terminated from the study (reasons for termination will be included in the consent form)
  • Medical conditions prior to pregnancy which could influence weight loss or gain: cystic fibrosis, hyperthyroidism, renal insufficiency1, proteinuria1, cerebral palsy, lupus erythematosus; rheumatoid arthritis, Crohns disease (severity and other autoimmune diseases evaluated case by case), ulcerative colitis, maternal congenital heart disease (patients are often underweight); hypertension treated with medication2,
  • Psychiatric medication associated with major weight gain or loss (e.g.; Lithium \& Divalproex) Common Criteria
  • Household member on study staff
  • Past or planned (within the next 24 months) weight loss surgery (e.g. gastric bypass, lap band, or liposuction); current participation in a commercial weight loss program (e.g. Weight Watcher's, Jenny Craig); currently enrolled or planned to enroll in a weight loss or another weight gain prevention study
  • Participants will be excluded during screening if they report regular use of systemic steroids, prescription weight loss drugs, and/or diabetes medications (oral or injected- insulin, metformin, byetta, TZDs, other). "Regular use" is defined as "taking this medication most days of the week for the previous month"
  • Current treatment for eating disorder
  • Positive screening for bulimia
  • Weight loss of more than 15 pounds in the three months prior to pregnancy
  • Cardiovascular event (heart attack, stroke, episode of heart failure, or revascularization procedure) within the last 6 month. Revascularization is defined as bypass surgery or stints
  • Mental or psychiatric condition that precludes giving informed consent and completing questionnaires
  • Current treatment for malignancy (other than non-melanoma skin cancer and CIN cervix) or on remission for less than 5 years
  • Blood pressure criterion
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,641 participants (actual)

Study arms

  • Experimental
    electronic intervention group 2

    (e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum

    Behavioral: electronic intervention during pregnancy and postpartum

  • Experimental
    electronic intervention group 1

    (e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm

    Behavioral: electronic intervention during pregnancy

  • Placebo comparator
    Control

    Behavioral: Control

Interventions

  • Behavioralelectronic intervention during pregnancy and postpartum

    Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention

    Also known as: Behavior modification intervention for pregnancy, Behavior modification intervention for postpartum, Prevention of excessive gestational weight gain, Prevention of postpartum weight retention, Electronically-mediated behavioral interventions

  • Behavioralelectronic intervention during pregnancy

    Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.

    Also known as: Behavior modification intervention for pregnancy, Prevention of excessive gestational weight gain, Electronically-mediated behavioral interventions

  • BehavioralControl

    Control women will receive non-weight related content during both time periods at the project website.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. Proportion of women whose gestational gain is within the recommended gestational weight gain Institute of Medicine Guidelines in kilograms

    Gestational weight gain is the result of the last predelivery weight minus the prepregnancy weight (or early pregnancy weight).

    Time frame: 40 weeks

  2. Postpartum weight retention in kg at 12 months postpartum

    The difference between the weight at 12 months postpartum and the pre-pregnancy weight (or early pregnancy weight. Participants will be followed for a maximum of 2 years from recruitment in early pregnancy to 18 months postpartum. The final outcome in the postpartum period is postpartum weight retention at 18 months. Interim measure of postpartum weight will be collected at 6 and 12 months for analyses. The primary hypothesis for the postpartum period is weight retention at 12 months postpartum.

    Time frame: 1.5 years

Secondary outcomes

  1. Caloric Intake in Kilocalories

    Caloric intake will be calculated based on the average food intake assessed by 2 24-hour dietary recall.

    Time frame: 2 years

  2. Physical activity as an average weekly energy expenditure (METS)

    Physical activity during pregnancy is measured using the Pregnancy Physical Activity Questionnaire and during postpartum using the Global Physical Activity Questionnaire.

    Time frame: 2 years

  3. Postpartum weight retention at 18 months

    The difference between the weight at 18 months postpartum and the prepregnancy weight (or early pregnancy weight). Participants will be followed for a maximum of 2 years from recruitment in early pregnancy to 18 months postpartum. The final outcome in the postpartum period is postpartum weight retention at 18 months. Interim measure of postpartum weight will be collected at 6 and 12 months for analyses. The primary hypothesis for the postpartum period is weight retention at 12 months postpartum

    Time frame: 2 years

07

Study locations

1 site
  • University of Rochester
    Rochester, New York 14642, United States
08

References and documents

Publications

  • Yu Y, Ma Q, Fernandez ID, Groth SW. Mental Health, Behavior Change Skills, and Eating Behaviors in Postpartum Women. West J Nurs Res. 2022 Oct;44(10):932-945. doi: 10.1177/01939459211021625. Epub 2021 Jun 4. PubMed 34088249 ↗
  • Olson CM, Groth SW, Graham ML, Reschke JE, Strawderman MS, Fernandez ID. The effectiveness of an online intervention in preventing excessive gestational weight gain: the e-moms roc randomized controlled trial. BMC Pregnancy Childbirth. 2018 May 9;18(1):148. doi: 10.1186/s12884-018-1767-4. PubMed 29743026 ↗
  • Olson CM, Strawderman MS, Graham ML. Association between consistent weight gain tracking and gestational weight gain: Secondary analysis of a randomized trial. Obesity (Silver Spring). 2017 Jul;25(7):1217-1227. doi: 10.1002/oby.21873. Epub 2017 Jun 2. PubMed 28573669 ↗
  • Graham ML, Strawderman MS, Demment M, Olson CM. Does Usage of an eHealth Intervention Reduce the Risk of Excessive Gestational Weight Gain? Secondary Analysis From a Randomized Controlled Trial. J Med Internet Res. 2017 Jan 9;19(1):e6. doi: 10.2196/jmir.6644. PubMed 28069560 ↗
  • Fernandez ID, Groth SW, Reschke JE, Graham ML, Strawderman M, Olson CM. eMoms: Electronically-mediated weight interventions for pregnant and postpartum women. Study design and baseline characteristics. Contemp Clin Trials. 2015 Jul;43:63-74. doi: 10.1016/j.cct.2015.04.013. Epub 2015 May 6. PubMed 25957183 ↗
  • Demment MM, Graham ML, Olson CM. How an online intervention to prevent excessive gestational weight gain is used and by whom: a randomized controlled process evaluation. J Med Internet Res. 2014 Aug 20;16(8):e194. doi: 10.2196/jmir.3483. PubMed 25143156 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01331564
Lead sponsor
University of Rochester
Collaborators
Cornell University
Responsible party
Diana Fernandez (Associate Professor of Public Health Sciences, University of Rochester) — Principal investigator
First posted
Apr 8, 2011
Start date
May 2011
Primary completion
May 2014
Completion
Dec 2014
Last update
Dec 2, 2015

Study contacts

Isabel D Fernandez, MD, MPH, PhD
principal investigator · University of Rochester
Christine M Olson, PhD
principal investigator · Cornell University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion